Klaus
Elenius
Professor, Institute of Biomedicine
Director, BioCity Turku
Turku Bioscience Centre
MD, PhD, professor
Research
ACTIONABLE RECEPTOR TYROSINE KINASE SIGNALING
Our goal is to understand how receptor tyrosine kinases (RTK) regulate the pathogenesis of human diseases, such as cancer. This information is needed for the development of molecularly targeted therapies. To recognize aberrations of RTK signaling in diseased tissue our laboratory also works on the molecular mechanism by which RTKs control normal processes, such as embryonic development. The work mainly focuses on the ErbB family of RTKs. Our laboratory has contributed to the field by e.g. by characterizing novel RTK signaling mechanisms, by identifying novel ErbB4 isoforms, and by determining the role of ErbBs and their ligands in angiogenesis.
Current topics
- Screens for predictive RTK mutations
- Novel RTK signaling mechanisms
- Development of preclinical models for development novel RTK inhibitors
- Sequencing of RTK inhibitor drug administration with cytotoxic agents
- In vitro “basket trials” with ErbB inhibitor drugs
- RTK signaling in angiogenesis and cardiovascular diseases
- RTKs in pediatric malignancies
- Biological role of novel ErbB4 isoforms in diseases and development
Elenius Lab members
- Anne Jokilammi, PhD
- Elli Narvi, PhD
- Deepankar Chakroborty, MSc
- Juho Heliste, MD
- Marika Koivu, MSc
- Johannes Merilahti, MSc
- Veera Ojala, MSc
- Janne Nordberg, MD
- Fred Saarinen, MSc
- Katri Vaparanta, MSc
- Kaisa Aalto, BM
- Maria Helkkula, BM
- Matias Mäenpää, BM
- Peppi Kirjalainen, BM
- Jori Torkkila, BM
Publications
Geeniohjatun syövän hoidon työryhmä hoitopäätösten apuna : Läntisen syöpäkeskuksen kokemus (2021)
Duodecim
(Artikkeli ammattilehdessä tai kirjoitus ammatillisessa blogissa (D1))
The impact of non-additive genetic associations on age-related complex diseases (2021)
Nature Communications
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Combined genetic and chemical screens indicate protective potential for EGFR inhibition to cardiomyocytes under hypoxia (2021)
Scientific Reports
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Chromosome Xq23 is associated with lower atherogenic lipid concentrations and favorable cardiometabolic indices (2021)
Nature Communications
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Genomic prediction of alcohol-related morbidity and mortality (2020)
Translational Psychiatry
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Erbb4 regulates the oocyte microenvironment during folliculogenesis (2020)
Human Molecular Genetics
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Rare protein-altering variants in ANGPTL7 lower intraocular pressure and protect against glaucoma (2020)
PLoS Genetics
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
A Platelet Function Modulator of Thrombin Activation Is Causally Linked to Cardiovascular Disease and Affects PAR4 Receptor Signaling (2020)
American Journal of Human Genetics
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Polygenic Hyperlipidemias and Coronary Artery Disease Risk (2020)
Circulation: Genomic and Precision Medicine
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Genetic analysis of obstructive sleep apnoea discovers a strong association with cardiometabolic health (2020)
European Respiratory Journal
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))